Figure 2. Change from baseline in acute migraine-specific medication treatment days over time.

Least-squares mean (LSM) changes from baseline in acute migraine-specific medication treatment days in patients (A) without and (B) with medication overuse among patients with chronic migraine who were assigned to receive placebo, erenumab 70 mg, or erenumab 140 mg every month. Error bars represent 95% confidence intervals (CIs). *p < 0.05, **p < 0.001 for erenumab vs placebo.